EWS & EVENTS
Agonist redirected checkpoint, PD1-Fc-OX40L, for cancer immunotherapy

Fromm et.al Journal for ImmunoTherapy of Cancer, 18 December 2018

Fromm et al. PD1-Fc-OX40L - JITC
MIGHT ALSO LIKE
YOU MIGHT ALSO LIKE
Shattuck Labs, Inc. Announces Initiation of Phase 1 Clinical Trial of SL-279252 (PD1/OX40L)

Shattuck Labs Press Release May 6, 2019  

Read more
Takeda and Shattuck Labs Announce Collaboration to Explore ARC Fusion Proteins in Immuno-Oncology

Press Release 2017

Read more